Figure 9 The evaluation of the efficacy of immunotherapy in different risk groups. (A–D) The results of TIDE, microsatellite instability, and T cell exclusion and dysfunction score in different risk groups (ns: not significant, * P<0.05, ** P<0.01, *** P<0.001). (E) Time-dependent ROC curve for 1-year, 2-year and 3-year predictions (our risk model). (F) ROC analysis of the risk model, TIDE and TIS on overall survival. TIDE – tumor immune dysfunction and exclusion; ROC – receiver operating characteristic; TIS – tumor inflammation signature.